Mandate

Vinge advises Investor Growth Capital

January 30, 2009

Vinge has advised Investor Growth Capital in connection with its investment in Synosia Therapeutics. Synosia Therapeutics is a company which develops and intends to commercialise innovative and clinically differentiated products for unfulfilled medical requirements within psychiatry and neurology.
 
Vinge’s team consisted of responsible partner Johan Winnerblad together with associate Karl Svantema.

Related

Vinge has advised Rite Ventures in connection with sale of shares in Qliro AB (publ)

Vinge has advised Rite Ventures in connection with the sale of shares in Qliro AB (publ) to Svea Bank AB (publ).
November 19, 2026

Vinge advises Röko AB (publ) in connection with the establishment of its MTN programme

Vinge has advised Röko AB (publ) ("Röko") on the establishment of a medium-term note programme (the "MTN Programme") with a framework amount of SEK 5 billion.
November 13, 2026

Vinge advises Telavox on the sale of its Nordic customer base to Telia

Vinge has advised Telavox AB (“Telavox”) on the sale of Telavox’s Nordic customer base for business services to Telia Company AB (“Telia”). The customer base comprises approximately 24,000 business customers and 325,000 end users in Sweden, Denmark, Finland, and Norway. The purchase price amounts to SEK 3.8 billion plus a potential additional earn-out.
November 13, 2026